INOVIO PHARMACEUTICALS, INC.
INONasdaq
$1.12
0.0%Jul 17 close · end-of-day
Price
1Y↓ -16.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$77.4M
Enterprise Value
$39.7M
P/E
—
P/S
—
P/B
12.8
EV/EBITDA
—
PEG
—
FCF Yield
-108.0%
Dividend Yield
—
Revenue (TTM)
$0.00
Net Income (TTM)
-$85.0M
Free Cash Flow (TTM)
-$83.6M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-1400.6%
ROIC
—
Debt / Equity
—
Net Cash
$37.7M
Return 1Y
-18.3%
Company profile
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines. Its DNA medicines platform uses precisely designed SynCon that identifies and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
- CEO
- Jacqueline E. Shea
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 320
- Headquarters
- Pennsylvania
- Website
- inovio.com
Management & directors
- Humeau LaurentChief Scientific Officer
- Kies PeterCFO
- Shea Jacqueline ElizabethChief Executive Officer
- Sumner Michael JohnChief Medical Officer
Roles derived from SEC Form 4 filings.
Earnings
INO Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$0.00↓ -100.0%
Diluted EPS-$0.28↓ -45.1%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $7.4M | $1.8M | $10.3M | $832,010.00 | $217,756.00 | $65,343.00 |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$124.1M | -$301.2M | -$267.6M | -$143.9M | -$112.4M | -$86.8M |
| Net income | -$166.4M | -$303.7M | -$279.8M | -$135.0M | -$107.0M | -$85.0M |
| Diluted EPS | -$1.07 | -$17.45 | -$14.07 | -$6.09 | -$3.95 | -$1.81 |
| Operating cash flow | -$178.0M | -$215.7M | -$216.2M | -$124.4M | -$104.1M | -$88.6M |
| Free cash flow | -$179.5M | -$216.9M | -$217.2M | -$124.7M | -$104.6M | -$88.9M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -1674.2% | -16972.3% | -2607.4% | -17300.3% | -51616.9% | -132871.3% |
| Net margin | -2245.4% | -17109.9% | -2726.7% | -16225.8% | -49137.6% | -130082.8% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $100,762.00 | $0.00 | $116,994.00 | $65,343.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$33.2M | -$27.3M | -$20.4M | -$25.1M | -$23.1M | -$21.2M | -$17.5M | -$21.9M |
| Net income | -$32.2M | -$25.2M | -$19.1M | -$19.7M | -$23.5M | -$45.5M | $3.7M | -$19.7M |
| Diluted EPS | -$1.19 | -$0.89 | -$0.56 | -$0.51 | -$0.61 | -$0.87 | $0.18 | -$0.28 |
| Operating cash flow | -$28.2M | -$27.4M | -$19.7M | -$26.9M | -$20.8M | -$21.6M | -$19.4M | -$21.6M |
| Free cash flow | -$28.7M | -$27.4M | -$19.7M | -$26.9M | -$20.8M | -$21.6M | -$19.5M | -$21.6M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -32945.9% | — | -17410.8% | -38337.0% | — | — | — | — |
| Net margin | -31993.3% | — | -16349.2% | -30140.5% | — | — | — | — |
Company news
May 28, 2026
May 25, 2026
May 21, 2026
May 14, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-20 | Shea Jacqueline Elizabeth· Chief Executive Officer | Tax withholding | 12,306 | $1.23 | $15,136.38 | filing |
| 2026-05-20 | KIES PETER· CFO | Tax withholding | 4,688 | $1.23 | $5,766.24 | filing |
| 2026-05-20 | Sumner Michael John· Chief Medical Officer | Tax withholding | 2,693 | $1.23 | $3,312.39 | filing |
| 2026-05-20 | Humeau Laurent· Chief Scientific Officer | Tax withholding | 2,163 | $1.23 | $2,660.49 | filing |
| 2026-05-20 | Humeau Laurent· Chief Scientific Officer | Option exercise | 6,027 | — | — | filing |
| 2026-05-20 | Sumner Michael John· Chief Medical Officer | Option exercise | 9,450 | — | — | filing |
| 2026-05-20 | KIES PETER· CFO | Option exercise | 8,700 | — | — | filing |
| 2026-05-20 | Shea Jacqueline Elizabeth· Chief Executive Officer | Option exercise | 28,296 | — | — | filing |
| 2026-05-15 | Shea Jacqueline Elizabeth· Chief Executive Officer | Tax withholding | 7,717 | $1.30 | $10,032.10 | filing |
| 2026-05-15 | KIES PETER· CFO | Tax withholding | 2,571 | $1.30 | $3,342.30 | filing |
| 2026-05-15 | Humeau Laurent· Chief Scientific Officer | Tax withholding | 1,712 | $1.30 | $2,225.60 | filing |
| 2026-05-15 | Sumner Michael John· Chief Medical Officer | Tax withholding | 680 | $1.30 | $884.00 | filing |
| 2026-05-15 | Humeau Laurent· Chief Scientific Officer | Option exercise | 4,771 | — | — | filing |
| 2026-05-15 | KIES PETER· CFO | Option exercise | 4,771 | — | — | filing |
| 2026-05-15 | Sumner Michael John· Chief Medical Officer | Option exercise | 2,385 | — | — | filing |
| 2026-05-15 | Shea Jacqueline Elizabeth· Chief Executive Officer | Option exercise | 17,744 | — | — | filing |
| 2026-03-31 | Sumner Michael John· Chief Medical Officer | Tax withholding | 1,223 | $1.74 | $2,128.02 | filing |
| 2026-03-31 | Sumner Michael John· Chief Medical Officer | Option exercise | 4,292 | — | — | filing |
| 2026-02-26 | Shea Jacqueline Elizabeth· Chief Executive Officer | Tax withholding | 13,657 | $1.79 | $24,446.03 | filing |
| 2026-02-26 | Shea Jacqueline Elizabeth· Chief Executive Officer | Tax withholding | 8,057 | $1.79 | $14,422.03 | filing |
| 2026-02-26 | KIES PETER· CFO | Tax withholding | 6,294 | $1.79 | $11,266.26 | filing |
| 2026-02-26 | Sumner Michael John· Chief Medical Officer | Tax withholding | 3,903 | $1.79 | $6,986.37 | filing |
| 2026-02-26 | Humeau Laurent· Chief Scientific Officer | Tax withholding | 3,034 | $1.79 | $5,430.86 | filing |
| 2026-02-26 | KIES PETER· CFO | Tax withholding | 2,965 | $1.79 | $5,307.35 | filing |
| 2026-02-26 | Humeau Laurent· Chief Scientific Officer | Tax withholding | 2,064 | $1.79 | $3,694.56 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.